To determine effect of body mass index (BMI) on safety and cancer-related outcomes of thermal ablation for renal cell carcinoma (RRC).
This retrospective study evaluated 427 patients (287 men and 140 women; mean [SD] age, 72 [12] y) who were treated with thermal ablation for RCC between October 2006 and December 2017. Patients were stratified by BMI into 3 categories: normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), and obese (≥ 30 kg/m2). Of 427 patients, 71 (16%) were normal weight, 157 (37%) were overweight, and 199 (47%) were obese. Complication rates, local recurrence, and residual disease were compared in the 3 cohorts.
No differences in technical success between normal-weight, overweight, and obese patients were identified (P = .72). Primary technique efficacy rates for normal-weight, overweight, and obese patients were 91%, 94%, and 93% (P = .71). There was no significant difference in RCC specific-free survival, disease-free survival, and metastasis-free survival between obese, overweight, and normal-weight groups (P = .72, P = .43, P = .99). Complication rates between the 3 cohorts were similar (normal weight 4%, overweight 2%, obese 3%; P = .71).
CT-guided renal ablation is safe, feasible, and effective regardless of BMI.
Journal of vascular and interventional radiology : JVIR. 2020 Dec 08 [Epub ahead of print]
Wenhui Zhou, Sanna E Herwald, Raul N Uppot, Ronald S Arellano
Department of Radiology, Stanford Medicine, Stanford, California., Department of Interventional Radiology, Massachusetts General Hospital, 55 Fruit Street, GRB 293, Boston, MA 02114., Department of Interventional Radiology, Massachusetts General Hospital, 55 Fruit Street, GRB 293, Boston, MA 02114. Electronic address: .